Credit Suisse’s AbbVie ABBV Stock Holding History

Credit Suisse’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-933,900	Closed	-$126M	–	3564
2021 Q4	$126M	Buy	933,900 +22,600	+2%	+$2.67M	0.07%	302
2021 Q3	$98.3M	Sell	911,300 -15,100	-2%	-$1.73M	0.05%	374
2021 Q2	$104M	Sell	926,400 -379,300	-29%	-$42.7M	0.06%	373
2021 Q1	$141M	Sell	1,305,700 -405,500	-24%	-$43.4M	0.07%	295
2020 Q4	$183M	Buy	1,711,200 +37,300	+2%	+$3.58M	0.09%	231
2020 Q3	$147M	Buy	1,673,900 +736,900	+79%	+$69.4M	0.09%	241
2020 Q2	$92M	Sell	937,000 -151,400	-14%	-$13.3M	0.07%	307
2020 Q1	$82.9M	Sell	1,088,400 -127,800	-11%	-$10.9M	0.07%	267
2019 Q4	$108M	Buy	1,216,200 +337,400	+38%	+$28M	0.08%	253
2019 Q3	$66.5M	Sell	878,800 -90,300	-9%	-$6.19M	0.06%	358
2019 Q2	$70.5M	Buy	969,100 +314,800	+48%	+$24.7M	0.06%	320
2019 Q1	$52.7M	Buy	654,300 +593,600	+978%	+$48.6M	0.05%	408
2018 Q4	$5.6M	Sell	60,700 -23,000	-27%	-$2.02M	0.01%	1503
2018 Q3	$7.92M	Buy	83,700 +49,800	+147%	+$4.72M	0.01%	1400
2018 Q2	$3.14M	Buy	+33,900	New	+$3.31M	﹤0.01%	2090
2018 Q1	–	Sell	-225,000	Closed	-$21.8M	–	3946
2017 Q4	$21.8M	Buy	225,000 +50,000	+29%	+$4.71M	0.02%	840
2017 Q3	$15.6M	Sell	175,000 -100,000	-36%	-$7.61M	0.02%	983
2017 Q2	$19.9M	Buy	275,000 +187,500	+214%	+$12.6M	0.02%	806
2017 Q1	$5.7M	Sell	87,500 -97,500	-53%	-$6.13M	0.01%	1562
2016 Q4	$11.6M	Sell	185,000 -200,000	-52%	-$12.2M	0.01%	1108
2016 Q3	$24.3M	Hold	385,000	–	–	0.02%	725
2016 Q2	$23.8M	Buy	385,000 +285,000	+285%	+$17.4M	0.03%	678
2016 Q1	$5.71M	Sell	100,000 -150,000	-60%	-$8.36M	0.01%	1439
2015 Q4	$14.8M	Buy	+250,000	New	+$14.4M	0.02%	942
2015 Q3	–	Sell	-80,000	Closed	-$5.38M	–	4236
2015 Q2	$5.38M	Buy	+80,000	New	+$5.22M	0.01%	1672

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Credit Suisse's ABBV Position: Q1 2024 in Review

Credit Suisse increased its AbbVie (ABBV) stake by 3.9% in Q1 2024, buying an estimated $17.5M and bringing the position to 2,736,828 shares worth $498M. The position accounts for 0.48% of the portfolio, ranked #28.

Credit Suisse first reported a position in ABBV in Q2 2013 and has held it in 44 quarters since. The position peaked at $542M in Q1 2022. 3,379 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.

Credit Suisse held 2,736,828 shares of AbbVie worth $498M as of Q1 2024.
Credit Suisse bought 101,696 AbbVie shares in Q1 2024, an estimated $17.5M.
AbbVie made up 0.48% of Credit Suisse's portfolio in Q1 2024, its #28 holding.
Credit Suisse first reported a position in AbbVie in Q2 2013 and has held it in 44 quarters since.
Credit Suisse's AbbVie position peaked at $542M in Q1 2022.
3,379 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.